Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 140-143

  Vergu, Elisabeta ^a   Mallet, Alain ^a   Golmard, Jean Louis ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Modelling; Resistance tests; Therapy outcome

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; EXPERIMENTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNE SYSTEM; IMMUNOGENICITY; INDIVIDUALIZATION; LYMPHOCYTE COUNT; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; PHENOTYPE; PREDICTION; REVIEW; STANDARDIZATION; STATISTICAL MODEL; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 1242285455     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh024     Document Type: Review

References (15)

1. Back, D., Gatti, G., Fletcher C. et al. (2002). Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16, Suppl. 1, 5-37.
2. Vergu, E., Mallet, A. & Golmard, J. L. (2002). The role of resistance characteristics of viral strains in the prediction of the response to antiretroviral therapy in HIV infection. Journal of Acquired Immune Deficiency Syndromes 30, 263-70.
3. Sterling, T. R., Chaisson, R. E. & Moore, R. D. (2001). HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 15, 2251-7.
4. Grabar, S., Le Moing, V., Goujard, C. et al. (2000). Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Annals of Internal Medicine 133, 401-10.
5. Deeks, S. G. (2000). Determinants of virological response to anti-retroviral therapy: implications for long-term strategies. Clinical Infectious Diseases 30, S177-84.
6. Chêne, G., May, R., Costagliola, D. et al. (2002). Prognosis of HIV-1 infected drug naive patients starting potent antiretroviral therapy. ART Cohort Collaboration. In Program and Abstracts of the XIV International AIDS Conference, Barcelona, Spain, 2002. Abstract TuOrB1140, p. 370. IAS International AIDS Society, Stockholm, Sweden.
7. Egger, M., May, M., Chêne, G. et al. (2002). Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360, 119-29.
8. Wilson, J. D. K., Ogg, G. S., Allen, R. L. et al. (2000). Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 14, 225-33.
9. Giorgi, J. V., Lyles, R. H., Matud, J. L. et al. (2002). Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 29, 346-55.
10. Macias, J., Leal, M., Delgado, J. et al. (2001). Usefulness of route of transmission, absolute CD8+ T-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1 infected patients with very low CD4+ T-cell counts. European Journal of Clinical Microbiology and Infectious Diseases 4, 253-9.
11. Xu, J., Whitman, L., Lori, F. et al. (2002). Quantification of HIV-specific CD8 T cells by in vitro stimulation with inactivated viral particles. AIDS 16, 1849-57.
12. DeGruttola, V., Dix, L., D'Aquila, R. et al. (2000). The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 5, 41-8.
13. Hanna, G. J. & D'Aquila, R. (2001). Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clinical Infectious Diseases 32, 774-82.
14. Haubrich, R. & Demeter, L. (2001). International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. Journal of Acquired Immune Deficiency Syndromes 26, S51-9.
15. Torre, D. & Tambini, R. (2002). Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clinical Trials 3, 1-8.